|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 23377 |
FusionGeneSummary for NAMPT_CD69 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: NAMPT_CD69 | Fusion gene ID: 23377 | Hgene | Tgene | Gene symbol | NAMPT | CD69 | Gene ID | 10135 | 969 |
| Gene name | nicotinamide phosphoribosyltransferase | CD69 molecule | |
| Synonyms | 1110035O14Rik|PBEF|PBEF1|VF|VISFATIN | AIM|BL-AC/P26|CLEC2C|EA1|GP32/28|MLR-3 | |
| Cytomap | 7q22.3 | 12p13.31 | |
| Type of gene | protein-coding | protein-coding | |
| Description | nicotinamide phosphoribosyltransferaseNAmPRTasepre-B cell-enhancing factorpre-B-cell colony-enhancing factor 1 | early activation antigen CD69C-type lectin domain family 2, member CCD69 antigen (p60, early T-cell activation antigen)activation inducer molecule (AIM/CD69)early T-cell activation antigen p60early lymphocyte activation antigenleukocyte surface anti | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | P43490 | Q07108 | |
| Ensembl transtripts involved in fusion gene | ENST00000222553, ENST00000354289, ENST00000484527, | ENST00000228434, ENST00000536709, | |
| Fusion gene scores | * DoF score | 3 X 3 X 1=9 | 1 X 1 X 1=1 |
| # samples | 3 | 1 | |
| ** MAII score | log2(3/9*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(1/1*10)=3.32192809488736 | |
| Context | PubMed: NAMPT [Title/Abstract] AND CD69 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | NAMPT | GO:0008286 | insulin receptor signaling pathway | 17983582 |
| Hgene | NAMPT | GO:0045944 | positive regulation of transcription by RNA polymerase II | 23001182 |
| Hgene | NAMPT | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 19727662 |
| Hgene | NAMPT | GO:0060612 | adipose tissue development | 17983582 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | DB135958 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000222553 | ENST00000228434 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| intron-3CDS | ENST00000222553 | ENST00000536709 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| intron-3CDS | ENST00000354289 | ENST00000228434 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| intron-3CDS | ENST00000354289 | ENST00000536709 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| intron-3CDS | ENST00000484527 | ENST00000228434 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
| intron-3CDS | ENST00000484527 | ENST00000536709 | NAMPT | chr7 | 105913035 | - | CD69 | chr12 | 9907769 | - |
Top |
FusionProtFeatures for NAMPT_CD69 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| NAMPT | CD69 |
| Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamidemononucleotide, an intermediate in the biosynthesis of NAD. It isthe rate limiting component in the mammalian NAD biosynthesispathway. The secreted form behaves both as a cytokine withimmunomodulating properties and an adipokine with anti-diabeticproperties, it has no enzymatic activity, partly because of lackof activation by ATP, which has a low level in extracellular spaceand plasma. Plays a role in the modulation of circadian clockfunction. NAMPT-dependent oscillatory production of NAD regulatesoscillation of clock target gene expression by releasing the coreclock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependentSIRT1-mediated suppression (By similarity).{ECO:0000250|UniProtKB:Q99KQ4, ECO:0000269|PubMed:24130902}. | Involved in lymphocyte proliferation and functions as asignal transmitting receptor in lymphocytes, natural killer (NK)cells, and platelets. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for NAMPT_CD69 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for NAMPT_CD69 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for NAMPT_CD69 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for NAMPT_CD69 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | NAMPT | C0009319 | Colitis | 1 | CTD_human |
| Hgene | NAMPT | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| Hgene | NAMPT | C0028754 | Obesity | 1 | CTD_human |
| Hgene | NAMPT | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |
| Tgene | CD69 | C0000786 | Spontaneous abortion | 1 | CTD_human |
| Tgene | CD69 | C0003864 | Arthritis | 1 | CTD_human |
| Tgene | CD69 | C0011854 | Diabetes Mellitus, Insulin-Dependent | 1 | CTD_human |
| Tgene | CD69 | C0993582 | Arthritis, Experimental | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|